However, downregulation of MIR17HG was observed in many types of cancer after analyzing the TCGA dataset, such as acute myeloid leukemia (6.91 vs. 32.83), ovary cancer (0.88 vs. 1.77) and pancreas adenocarcinoma (0.84 vs. 1.64), which suggests the tumor suppressive roles of MIR17HG in these types of cancer. Here, MIR17HG is linked to ovarian cancer.